Understanding Low Risk MDS 2021 Winter Patient Family Conference | Aplastic Anemia & MDS International Foundation
Low-Risk MDS: Can We Prevent Progression? - YouTube
Frontiers | Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆ - Annals of Oncology
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS) - ScienceDirect
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? - ScienceDirect
Immunologic and Infectious Basis for Dysplastic Hematopoeisis
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes | MedPage Today
Diagnostic algorithm for lower-risk myelodysplastic syndromes | Leukemia
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes | PNAS
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study - The Lancet Oncology
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management - Garcia‐Manero - 2020 - American Journal of Hematology - Wiley Online Library
Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies: Trends in Molecular Medicine
Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes | Leukemia
Focus on Anemia in Managing Lower-Risk Myelodysplastic Syndromes
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome | Haematologica
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? - ScienceDirect
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Current and Emerging Therapies for Myelodysplastic Syndromes (MDS) Transcript
Diagnostics | Free Full-Text | From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Evolving therapies for lower-risk myelodysplastic syndromes | SpringerLink
Myelodysplastic Syndromes: Therapy and Outlook
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome | Haematologica
Living with Higher-Risk Myelodysplastic Syndromes - CONQUER: the journey informed
